title: Advances in therapies for non-Hodgkin lymphoma in children.
abstract: Pediatric patients with newly diagnosed, non-Hodgkin Lymphoma (NHL) have an excellent overall survival. However, therapy regimens are associated with acute toxicity and late effects. Furthermore, patients with relapsed or refractory disease have relatively few options with proven clinical benefit. Both histologic and molecular differences exist between adult and pediatric NHL preventing simple translation of adult NHL successes into improvements in pediatric NHL treatment. This review summarizes the introduction of targeted therapies into frontline treatments for patients with anaplastic large-cell lymphoma and CD20-positive tumors, with the goal of improving overall survival while limiting both short- and long-term toxicities. In addition, newer approaches that have limited data in children but may have a significant role in how we treat pediatric NHL in the future are reviewed, which include CD19 directed therapy, Notch inhibition, the tri-functional antibody, FBTA05, and EZH2 inhibition.
authors.affiliation: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: Rachel
authors.initials: R
authors.lastname: Kobos
authors.affiliation: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
authors.forename: William
authors.initials: W
authors.lastname: Terry
mesh_terms: D000328:Adult; D018033:Antibodies, Bispecific / Q000627:therapeutic use; D018941:Antigens, CD19 / Q000378:metabolism; D018951:Antigens, CD20 / Q000378:metabolism; D000079963:Brentuximab Vedotin; D002648:Child; D000077547:Crizotinib; D018572:Disease-Free Survival; D000071221:Enhancer of Zeste Homolog 2 Protein; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000097:blood; D017728:Lymphoma, Large-Cell, Anaplastic / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D008495:Medical Oncology / Q000379:methods; D063151:Polycomb Repressive Complex 2 / Q000037:antagonists & inhibitors; D011720:Pyrazoles / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D018033:Antibodies, Bispecific; D018941:Antigens, CD19; D018951:Antigens, CD20; C530113:Bi20 antibody; D018796:Immunoconjugates; D007074:Immunoglobulin G; D011720:Pyrazoles; D011725:Pyridines; C510808:blinatumomab; D000077547:Crizotinib; D000079963:Brentuximab Vedotin; C498409:EZH2 protein, human; D000071221:Enhancer of Zeste Homolog 2 Protein; D063151:Polycomb Repressive Complex 2